Table 2.
Bivariable analyses of characteristics among participants who exhibited seroreversion versus persistent nontreponemal antibody titers at 12 months (despite an appropriate serological treatment response), and adjusted model for characteristics associated with seroreversion.
| Characteristics | Seroreversion within 12 Months | Reactive RPR at 12 Months | OR (95% CI) | AOR (95% CI) |
|---|---|---|---|---|
| Male | 49 (23.3 %) | 161 (76.7 %) | 4.4 (2.0, 9.6) | 4.3 (1.8, 10.5) |
| Female | 8 (6.5 %) | 115 (93.5 %) | * | * |
| Malagasy | 42 (15.1%) | 237 (85.0 %) | 0.4 (0.1, 1.7) | 0.2 (0.1, 1.3) |
| Black | 12 (26.7 %) | 33 (73.3 %) | 0.7 (0.2, 3.9) | 0.8 (0.1, 4.7) |
| White + other | 3 (33.3 %) | 6 (66.7 %) | * | * |
| Stage: Primary | 32 (37.2 %) | 54 (62.8 %) | 5.1 (2.3, 12.7) | ----- |
| Stage: Secondary | 17 (10.0 %) | 153 (90.0 %) | 1.0 (0.4, 2.4) | ----- |
| Stage: Early Latent | 8 (10.4 %) | 69 (89.6 %) | * | ----- |
| Baseline RPR Titers ≤ 1:32 | 46 (41.1 %) | 66 (58.9 %) | 13.3 (6.5, 27.1) | 14.5 (6.8, 31.2) |
| Baseline RPR Titers > 1:32 | 11 (5.0 %) | 210 (95.0 %) | * | * |
| Penicillin | 32 (19.1 %) | 136 (81.0 %) | 1.3 (0.7, 2.3) | ----- |
| Azithromycin | 25 (15.2 %) | 140 (84.9 %) | * | ----- |
RPR= rapid plasma reagin; OR= odds ratio based on bivariate results; CI, confidence interval; AOR= adjusted odds ratio based on model
*
Reference category